Metabotropic glutamate receptor 5 antagonist protects dopaminergic and noradrenergic neurons from degeneration in MPTP-treated monkeys

Glutamate Receptors as Therapeutic Targets for Parkinsons Disease

(2012) Kari Johnson et al.   CNS & Neurological Disorders-Drug Targets

Subthalamic neuronal firing in obsessive-compulsive disorder and Parkinson disease

(2010) Brigitte Piallat et al.   ANNALS OF NEUROLOGY

Metabotropic Glutamate Receptors: Physiology, Pharmacology, and Disease

(2010) Colleen M. Niswender et al.   Annual Review of Pharmacology and Toxicology

Gene–Environment Interactions in Parkinson's Disease: The Importance of Animal Modeling

(2010) M P Horowitz et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Activation of type 5 metabotropic glutamate receptors attenuates deficits in cognitive flexibility induced by NMDA receptor blockade

(2010) Mark R. Stefani et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

18F-FECNT: Validation as PET dopamine transporter ligand in parkinsonism

(2010) Gunasingh Masilamoni et al.   EXPERIMENTAL NEUROLOGY

Neuroinflammation is associated with changes in glial mGluR5 expression and the development of neonatal excitotoxic lesions

(2010) Janelle Drouin-Ouellet et al.   GLIA

Reduction of L-DOPA-Induced Dyskinesia by the Selective Metabotropic Glutamate Receptor 5 Antagonist 3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Lesioned Macaque Model of Parkinson's Disease

(2010) T. H. Johnston et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Discovery of Novel Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 5 Reveals Chemical and Functional Diversity and In Vivo Activity in Rat Behavioral Models of Anxiolytic and Antipsychotic Activity

(2010) A. L. Rodriguez et al.   MOLECULAR PHARMACOLOGY

A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys

(2010) Daniella Rylander et al.   NEUROBIOLOGY OF DISEASE

Effect of the metabotropic glutamate receptor type 5 antagonists MPEP and MTEP in parkinsonian monkeys

(2010) Nicolas Morin et al.   NEUROPHARMACOLOGY

Activation of metabotropic glutamate receptor 5 improves recovery after spinal cord injury in rodents

(2009) Kimberly R. Byrnes et al.   ANNALS OF NEUROLOGY

Mitochondrial dysfunction in Parkinson's disease

(2009) Konstanze F. Winklhofer et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Neurotransmission in Parkinson’s disease: beyond dopamine

(2009) P. Barone   EUROPEAN JOURNAL OF NEUROLOGY

Glutamate, excitotoxicity, and programmed cell death in parkinson disease

(2009) W. Michael Caudle et al.   EXPERIMENTAL NEUROLOGY

Mitochondrial dynamics in Parkinson's disease

(2009) Victor S. Van Laar et al.   EXPERIMENTAL NEUROLOGY

A pilot open label, single dose trial of fenobam in adults with fragile X syndrome

(2009) E Berry-Kravis et al.   JOURNAL OF MEDICAL GENETICS

Pharmacological Modulation of Glutamate Transmission in a Rat Model of L-DOPA-Induced Dyskinesia: Effects on Motor Behavior and Striatal Nuclear Signaling

(2009) D. Rylander et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Can we achieve neuroprotection with currently available anti-parkinsonian interventions?

(2009) C. W. Olanow   NEUROLOGY

The locus ceruleus norepinephrine system: Functional organization and potential clinical significance

(2009) E. E. Benarroch   NEUROLOGY

Calcium homeostasis, selective vulnerability and Parkinson's disease

(2009) C. Savio Chan et al.   TRENDS IN NEUROSCIENCES

The promiscuous mGlu5 receptor – a range of partners for therapeutic possibilities?

(2009) Michael K. Bird et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Targets for neuroprotection in Parkinson's disease

(2008) Talene A. Yacoubian et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Imaging neurodegeneration in Parkinson's disease

(2008) Nicola Pavese et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Functional Neuroanatomy of the Noradrenergic Locus Coeruleus: Its Roles in the Regulation of Arousal and Autonomic Function Part II: Physiological and Pharmacological Manipulations and Pathological Alterations of Locus Coeruleus Activity in Humans

(2008) E. Samuels et al.   Current Neuropharmacology

Progress in neuroprotection in Parkinson’s disease

(2008) A. H. V. Schapira   EUROPEAN JOURNAL OF NEUROLOGY

Neuronal activity in the subthalamic nucleus modulates the release of dopamine in the monkey striatum

(2008) Yasushi Shimo et al.   EUROPEAN JOURNAL OF NEUROSCIENCE

Quantitative Analysis of Norepinephrine Transporter in the Human Brain Using PET with (S,S)-18F-FMeNER-D2

(2008) R. Arakawa et al.   JOURNAL OF NUCLEAR MEDICINE

The neuropathological basis for depression in Parkinson's disease

(2008) Pasquale G. Frisina et al.   PARKINSONISM & RELATED DISORDERS

Systemic administration of an mGluR5 antagonist, but not unilateral subthalamic lesion, counteracts l-DOPA-induced dyskinesias in a rodent model of Parkinson's disease

(2007) Giovanna Levandis et al.   NEUROBIOLOGY OF DISEASE